Euvic S.A. (Euvic Group) is diversifying its business by expanding its investment portfolio into new areas of activity. The latest investment by the Gliwice-based company involves acquiring a 10% stake in Proacta S.A., a company listed on the New Connect Alternative Trading System, specializing in developing IT solutions for medicine and bioinformatics based on artificial intelligence.
The Euvic Group continuously develops its core areas of business, which are centered around the pillars of Software Development, Body/Team Leasing, IT Infrastructure, Innovation, Performance, and Commerce Transformation. At the same time, the company is keeping an eye on trends and responding to market changes by diversifying its operations, thereby strengthening the Group’s position in both Polish and international markets.
"Artificial intelligence, machine learning, NLP, and data analysis are technologies that dominate and will continue to dominate the most innovative projects. Although artificial intelligence is still in its early stages, its potential is enormous. At the same time, we have been observing a market specialization and a shift in customer demands—they are increasingly expecting more domain knowledge, deeper expertise, and consultancy in technology projects. Proacta harnesses the potential of AI, possesses strong expertise in medtech and bioinformatics, and has experience in IT consulting. This is an investment in the future and in new directions for the Group's development," commented Wojciech Wolny, CEO of Euvic S.A.
Proacta has been delivering IT projects for over 15 years. The company uses its AI tools and the analysis of medical and biological data to develop new therapies, drugs, and diagnostic methods. Proacta invests in the development of its own products and technologies, which are the result of research and experience gained from projects executed for clients in global markets. Its team consists of experts specializing in the analysis of medical and genetic data using machine learning and artificial intelligence (AI/ML). The team includes bioinformaticians and molecular biologists, NLP (Natural Language Processing) engineers, machine learning and neural network experts, data security and privacy specialists, as well as doctors from various specialties.
"We made the decision to engage in solving real problems in the healthcare system using the latest technologies in 2018. Since then, we have deepened our expertise and developed advanced services and products for the medical sector. We are investing in the technological development of the company and scaling the business. We aspire to be a leader in bioinformatics not only in Poland but also globally. Collaboration with the Euvic Group is a significant boost to achieving our plans and an opportunity to develop further innovative projects together with the Group's companies," said Paweł Ciesielka, CEO of Proacta S.A."
